Drug Interactions between Cardizem and Viagra
This report displays the potential drug interactions for the following 2 drugs:
- Cardizem (diltiazem)
- Viagra (sildenafil)
Interactions between your drugs
dilTIAZem sildenafil
Applies to: Cardizem (diltiazem) and Viagra (sildenafil)
MONITOR CLOSELY: Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and effects of sildenafil, which is primarily metabolized by the isoenzyme. Pharmacokinetic studies have been conducted in healthy male volunteers using erectile dysfunction dosing for sildenafil. When administered to volunteers on the moderate to strong CYP450 3A4 inhibitors erythromycin (500 mg twice daily) or un-boosted saquinavir (1200 mg three times daily), each at steady state, the systemic exposure (AUC) of oral sildenafil (100 mg) increased by approximately 182% and 210%, respectively. Similarly, sildenafil's AUC increased by approximately 2-fold in volunteers who received a single dose of the moderate CYP450 3A4 inhibitor ciprofloxacin (500 mg) followed 2 hours later by a single oral dose of sildenafil (50 mg). An analysis of population pharmacokinetic data from clinical trials in adult pulmonary hypertension patients indicated a reduction in sildenafil's clearance of approximately 30% when it was coadministered with moderate CYP450 3A4 inhibitors. This analysis found a wide concentration range for oral sildenafil, as a dosage of 80 mg three times a day led to a systemic exposure of sildenafil that was 5 times greater than the standard 20 mg three times daily dose. This wide range may therefore cover the potential increased exposure from coadministration with CYP450 3A4 inhibitors less potent than ketoconazole, itraconazole, and ritonavir. Pharmacokinetic models predict that this interaction may be more significant for oral rather than intravenous (IV) formulations of sildenafil, due at least partly to effects from first pass metabolism. However, one physiologically-based pharmacokinetic model used to analyze the effects of IV fluconazole on IV sildenafil predicted an increase in sildenafil's AUC of 2.11-fold in adults and 2.82-fold in infants.
MANAGEMENT: Caution and close clinical monitoring are advised if sildenafil is coadministered with a moderate CYP450 3A4 inhibitor. The severity of this interaction may be increased in the presence of renal and/or hepatic dysfunction, potentially requiring dosage adjustments. When used in the treatment of pulmonary arterial hypertension in adults, some authorities recommend considering a dose reduction for sildenafil to 20 mg oral (10 mg IV) twice daily in the presence of a 3A4 inhibitor like erythromycin. For erectile dysfunction, the US labeling recommends considering a starting dose of 25 mg in patients taking erythromycin or stronger CYP450 3A4 inhibitors. The labeling for the CYP450 3A4 inhibitor should also be consulted as some may have additional recommendations or guidance, such as specific information on the potency of the CYP450 3A4 inhibitor and how long the inhibition may persist after the last dose of the inhibitor. Regardless of indication, all patients should be advised to promptly notify their physician if they experience serious side effects from sildenafil such as pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, low blood pressure, sudden decrease or loss of hearing, visual disturbances, syncope, or prolonged erection (greater than 4 hours).
References (18)
- (2001) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals
- Khoury V, Kritharides L (2000) "Diltiazem-mediated inhibition of sildenafil metabolism may promote hypotension nitrate-induced." Aust N Z J Med, 30, p. 641-2
- Hedaya MA, El-Afify DR, El-Maghraby GM (2006) "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos, 27, p. 103-10
- (2023) "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group, SUPPL-25
- (2023) "Product Information. Revatio (sildenafil)." Pfizer Australia Pty Ltd
- (2021) "Product Information. Wafesil (sildenafil)." iX Biopharma Pty Ltd
- (2021) "Product Information. Silcap (sildenafil)." iX Biopharma Pty Ltd
- (2023) "Product Information. Viagra Connect (sildenafil)." Viatris UK Healthcare Ltd
- (2023) "Product Information. Revatio (sildenafil)." Pfizer Ltd
- (2022) "Product Information. Sildenafil (sildenafil)." Rosemont Pharmaceuticals Ltd
- (2022) "Product Information. Sildenafil (Lupin) (sildenafil)." Generic Health Pty Ltd, v1
- (2021) "Product Information. Revatio (sildenafil)." Pfizer Canada Inc
- (2022) "Product Information. Priva-Sildenafil (sildenafil)." Pharmapar Inc
- (2023) "Product Information. Sildenafil (sildenafil)." Amarox Ltd
- (2022) "Product Information. Sildenafil Citrate (sildenafil)." Torrent Pharma Inc
- Salerno SN, Edginton A, Gerhart JG, et al. (2021) "Physiologically-based pharmacokinetic modeling characterizes the CYP3A-mediated drug-drug interaction between fluconazole and sildenafil in infants." Clin Pharmacol Ther, 109, p. 253-62
- (2023) "Product Information. Ciprofloxacin Hydrochloride (ciprofloxacin)." Hospira Inc
- Muirhead GJ, faulkner s, Harness JA, Taubel J (2002) "The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers." Br J Clin Pharmacol, 53, 37S-43S
Drug and food interactions
dilTIAZem food
Applies to: Cardizem (diltiazem)
MONITOR: Like many CNS-active agents, alcohol can exhibit hypotensive effects. Coadministration with antihypertensive agents including diltiazem may result in additive effects on blood pressure and orthostasis.
MONITOR: Grapefruit juice may increase the plasma concentrations of orally administered diltiazem in some patients. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In a study of ten healthy male volunteers, administration of a single 120 mg oral dose of immediate-release diltiazem in combination with 250 mL of grapefruit juice increased the diltiazem peak plasma concentration (Cmax) and systemic exposure (AUC) by an average of 22% and 20%, respectively, compared to administration with water. The time to reach Cmax (Tmax) and the terminal half-life were not affected, and no statistically significant differences in blood pressure and heart rate were observed during administration with grapefruit juice relative to water. In a different study, repeated administration of 200 mL of grapefruit juice at 0, 2, 4, 8 and 12 hours had no significant effect on the Cmax or AUC of a single 120 mg oral dose of diltiazem, but increased its half-life from 4.1 to 5.1 hours. The ratios for the N-demethyl and deacetyl metabolites to diltiazem were also not affected by grapefruit juice. However, because pharmacokinetic interactions involving grapefruit juice are often subject to a high degree of interpatient variability, the extent to which a given patient may be affected is difficult to predict.
MANAGEMENT: Patients should be advised that alcohol may potentiate the hypotensive effects of diltiazem, especially during the initiation of therapy and following a dosage increase. Caution should be exercised when rising from a sitting or recumbent position, and patients should notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients who regularly consume grapefruit or grapefruit juice should be monitored for increased adverse effects of diltiazem such as such as headache, irregular heartbeat, edema, unexplained weight gain, and chest pain. Grapefruit and grapefruit juice should be avoided if an interaction is suspected.
References (5)
- Bailey DG, Arnold JMO, Spence JD (1994) "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet, 26, p. 91-8
- Sigusch H, Henschel L, Kraul H, Merkel U, Hoffmann A (1994) "Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects." Pharmazie, 49, p. 675-9
- Bailey DG, Malcolm J, Arnold O, Spence JD (1998) "Grapefruit juice-drug interactions." Br J Clin Pharmacol, 46, p. 101-10
- Christensen H, Asberg A, Holmboe AB, Berg KJ (2002) "Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers." Eur J Clin Pharmacol, 58, p. 515-520
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
sildenafil food
Applies to: Viagra (sildenafil)
GENERALLY AVOID: Coadministration with grapefruit juice may slightly increase the oral bioavailability and delay the onset of action of sildenafil. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. In a randomized, crossover study with 24 healthy male volunteers, ingestion of 250 mL of grapefruit juice one hour before and concurrently with a 50 mg dose of sildenafil increased the mean area under the plasma concentration-time curve (AUC) of sildenafil and its pharmacologically active N-desmethyl metabolite by 23% and 24%, respectively, compared to water. Peak plasma concentrations (Cmax) were unaltered, but the time to reach sildenafil Cmax was prolonged by 0.25 hour. The observed increase in sildenafil bioavailability is unlikely to be of clinical significance in most individuals. However, pharmacokinetic interactions involving grapefruit juice are often subject to a high degree of interpatient variability and may be significant in the occasional susceptible patient. Indeed, one subject in the study had a 2.6-fold increase in sildenafil concentrations.
MANAGEMENT: It may be advisable to avoid administration of sildenafil with grapefruit juice to prevent potential toxicity and delay in onset of action.
References (1)
- Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. (2002) "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther, 71, p. 21-29
dilTIAZem food
Applies to: Cardizem (diltiazem)
MONITOR: Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.
MANAGEMENT: Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.
References (14)
- Henry M, Kay MM, Viccellio P (1985) "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med, 3, p. 334-6
- Moller IW (1987) "Cardiac arrest following intravenous verapamil combined with halothane anaesthesia." Br J Anaesth, 59, p. 522-6
- Oszko MA, Klutman NE (1987) "Use of calcium salts during cardiopulmonary resuscitation for reversing verapamil-associated hypotension." Clin Pharm, 6, p. 448-9
- Schoen MD, Parker RB, Hoon TJ, et al. (1991) "Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects." Am J Cardiol, 67, p. 300-4
- O'Quinn SV, Wohns DH, Clarke S, Koch G, Patterson JH, Adams KF (1990) "Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing." Pharmacotherapy, 10, p. 247
- Woie L, Storstein L (1981) "Successful treatment of suicidal verapamil poisoning with calcium gluconate." Eur Heart J, 2, p. 239-42
- Morris DL, Goldschlager N (1983) "Calcium infusion for reversal of adverse effects of intravenous verapamil." JAMA, 249, p. 3212-3
- Guadagnino V, Greengart A, Hollander G, Solar M, Shani J, Lichstein E (1987) "Treatment of severe left ventricular dysfunction with calcium chloride in patients receiving verapamil." J Clin Pharmacol, 27, p. 407-9
- Luscher TF, Noll G, Sturmer T, Huser B, Wenk M (1994) "Calcium gluconate in severe verapamil intoxication." N Engl J Med, 330, p. 718-20
- Bar-Or D, Gasiel Y (1981) "Calcium and calciferol antagonise effect of verapamil in atrial fibrillation." Br Med J (Clin Res Ed), 282, p. 1585-6
- Lipman J, Jardine I, Roos C, Dreosti L (1982) "Intravenous calcium chloride as an antidote to verapamil-induced hypotension." Intensive Care Med, 8, p. 55-7
- McMillan R (1988) "Management of acute severe verapamil intoxication." J Emerg Med, 6, p. 193-6
- Perkins CM (1978) "Serious verapamil poisoning: treatment with intravenous calcium gluconate." Br Med J, 2, p. 1127
- Moroni F, Mannaioni PF, Dolara A, Ciaccheri M (1980) "Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning." Clin Toxicol, 17, p. 395-400
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.